Frontiers in Clinical Diabetes and Healthcare·4 AugDapagliflozin & pioglitazone combination therapy in T2DM with or without MASLD - a systematic review and meta-analysis: PRO-2 studyReviewInterventionsPaper
AHA Scientific Sessions 2025 Abstract·3 Nov37,500 man-years of clinical expertise validate the cardio-metabolic benefits of empagliflozin-linagliptin in type 2 diabetes: findings from the amplified consensusInterventionsPaper
ADA Scientific Sessions 2025 Abstract·13 JunDigital Twin Technology for Improvement In Extraglycemic Parameters—Three-Year Results of the Randomized Clinical TrialTrial in peopleInterventionsPaper